Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
The study will capture post-marketing safety data on patients treated with eculizumab or
 ravulizumab. Additionally, the study will collect information on the progression of disease
 in all patients.
Inclusion Criteria:

 -  Male or female patients of any age, including minors, who have been diagnosed with
 aHUS

 -  Patients with or without an identified complement pathogenic variant or
 anti-complement factor antibody

 -  Able to give written informed consent. Patient or patient's parent/legal guardian must
 be willing and able to given written informed consent and the patient (if minor) must
 be willing to give written informed assent [if applicable as determined by the central
 Institutional Review Boards/Independent Ethics Committees (IRB/IEC)].

 -  ADAMTS13 > 5%, if performed.

 Exclusion Criteria:

 -  Hemolytic Uremic Syndrome (HUS) only due to Shiga Toxin

 -  Unable to give written informed consent. Patient or patient's parent/legal guardian
 unable to give written informed consent. Patient (if minor) unable to give written
 informed assent (if applicable as determined by the central Institutional Review
 Boards/Independent Ethics Committees [IRB/IEC]).